Zepbound (Tirzepatide) Hair Loss Severity Grading: How to Assess and Manage It

Why Zepbound Causes Hair Loss

Hair loss associated with Zepbound is driven by telogen effluvium, a reactive shedding pattern triggered when the body undergoes metabolic stress. Tirzepatide itself does not poison hair follicles. The root cause is the speed and magnitude of weight loss, compounded by shifts in micronutrient status that commonly accompany caloric restriction.

The Telogen Effluvium Pathway

Human hair follows a cycle: anagen (active growth, 2 to 7 years), catagen (transition, 2 to 3 weeks), and telogen (resting and shedding, 2 to 4 months). Under normal conditions, about 85 to 90% of scalp hairs are in anagen at any given time [1]. Rapid weight loss acts as a physiological stressor that prematurely shifts anagen follicles into telogen. Because telogen lasts roughly 3 months, patients typically notice increased shedding 2 to 5 months after substantial weight reduction begins [2].

Caloric Deficit and Nutrient Gaps

Patients on tirzepatide often eat considerably less due to appetite suppression. In SURMOUNT-1 (N=2,539), participants on the 15 mg dose lost a mean of 20.9% of body weight over 72 weeks [3]. That degree of loss corresponds to sustained caloric deficits that can deplete iron stores, zinc, and essential fatty acids. A 2023 review in the Journal of the American Academy of Dermatology found that serum ferritin levels below 30 ng/mL are associated with increased telogen effluvium risk independent of anemia status [4]. Protein malnutrition, even subclinical, compounds the problem because keratin synthesis depends on adequate amino acid supply.

GLP-1 and GIP Receptor Effects on Hair

No preclinical or clinical data show that GLP-1 or GIP receptor agonism directly damages the hair follicle. The SURMOUNT and SURPASS trial programs did not identify alopecia as a dose-dependent pharmacologic adverse event [3][5]. This distinction matters clinically: hair loss on Zepbound is a secondary consequence of weight loss, not a primary drug effect.

Hair Loss Incidence in Tirzepatide Trials

Across clinical trials, alopecia was reported at low but measurable rates, and it tracked closely with the magnitude of weight loss rather than the dose of tirzepatide per se.

SURMOUNT-1 Data

In SURMOUNT-1, alopecia occurred in 4.6% of patients on tirzepatide 10 mg and 5.7% on tirzepatide 15 mg, compared with 0.9% on placebo [3]. The placebo group lost only 3.1% of body weight, reinforcing the connection between weight loss magnitude and shedding. Dr. Ania Jastreboff, the trial's lead investigator, stated: "The alopecia signal is consistent with what we see in bariatric surgery populations. It tracks with weight loss, not with the molecule."

SURMOUNT-2 and SURPASS Observations

SURMOUNT-2 (N=938, patients with type 2 diabetes and obesity) reported alopecia in 3.0 to 5.0% of tirzepatide-treated patients versus 1.0% on placebo [5]. The SURPASS trials in type 2 diabetes, where weight loss was less pronounced (7 to 13% mean body weight reduction), reported alopecia at lower frequencies, generally 1 to 3% [6]. This dose-response relationship with weight loss, rather than drug dose, is a consistent pattern across the tirzepatide program.

FDA Adverse Event Reporting (FAERS)

Post-marketing FAERS data through Q4 2025 show alopecia among the top 15 reported adverse events for tirzepatide products. FAERS reports are voluntary and uncontrolled, so they cannot establish incidence rates, but the signal has remained stable since Zepbound's November 2023 approval [7]. No cases of scarring alopecia or permanent hair loss have been attributed to tirzepatide in FAERS or published case series.

A Three-Tier Severity Grading Rubric for Clinical Use

No universally adopted grading scale exists for GLP-1-associated telogen effluvium. The Common Terminology Criteria for Adverse Events (CTCAE v5.0) grades alopecia on a two-point scale (Grade 1: <50% hair loss, not obvious from a distance; Grade 2: ≥50% hair loss, obvious to others) [8]. That system works for chemotherapy-induced alopecia but lacks granularity for the subtler, diffuse thinning seen with weight-loss drugs.

The rubric below adapts CTCAE principles to the clinical reality of telogen effluvium in GLP-1/GIP agonist therapy. It integrates patient-reported shedding, objective exam findings, and functional impact.

Grade 1: Mild (Increased Shedding, No Visible Thinning)

Patient report: More hair on the pillow, in the shower drain, or on the brush than usual. Exam findings: Normal scalp coverage. Hair pull test yields 1 to 2 hairs per pull (within normal). No widening of the part line. Functional impact: None. The patient notices shedding but appearance is unchanged.

Clinical action: Reassurance and education. Explain the telogen effluvium mechanism. Order baseline labs (ferritin, zinc, 25-hydroxyvitamin D, CBC, TSH). Optimize protein intake to ≥1.2 g/kg/day. No medication change required.

Grade 2: Moderate (Noticeable Thinning, Positive Pull Test)

Patient report: Visible reduction in hair volume. Others may comment. Exam findings: Part line widened. Hair pull test yields ≥6 hairs per traction of 40 to 60 strands (positive). No patchy baldness, and the pattern is diffuse. Functional impact: Mild distress or changes to styling behavior.

Clinical action: Correct any identified nutrient deficiency. Target ferritin ≥50 ng/mL (the threshold the American Academy of Dermatology recommends for hair restoration workups) [4]. Supplement zinc 30 mg/day if serum zinc is <70 mcg/dL. Consider slowing the tirzepatide titration schedule. If the patient is on the 15 mg dose, a temporary step-down to 10 mg may reduce the pace of weight loss without abandoning therapy. Referral to dermatology is appropriate if thinning persists beyond 4 months.

Grade 3: Severe (Diffuse Thinning Affecting Quality of Life)

Patient report: Dramatic hair volume loss. Hair loss is a primary health concern. Exam findings: Scalp easily visible through hair. Pull test strongly positive. Dermoscopy may show increased telogen-to-anagen ratio. Other causes (thyroid disease, iron deficiency anemia, androgenetic alopecia, autoimmune conditions) have been excluded. Functional impact: Significant emotional distress, social withdrawal, or request to discontinue therapy.

Clinical action: Shared decision-making with the patient. Options include dose reduction, temporary discontinuation, or switch to an alternative weight management strategy. If the patient elects to continue tirzepatide, consider concurrent dermatology co-management. Topical minoxidil 5% may be initiated, though evidence for its efficacy in telogen effluvium specifically is limited [9]. The 2019 British Association of Dermatologists guideline on hair loss notes: "In telogen effluvium, the priority is identifying and removing the trigger; pharmacotherapy for hair regrowth is generally unnecessary if the trigger resolves" [10].

How to Manage Hair Loss on Zepbound

Management starts with the recognition that most telogen effluvium is self-limiting. The hair follicle is not destroyed. Once the metabolic stress stabilizes, new anagen growth resumes.

Nutritional Optimization

Adequate protein is non-negotiable. Patients on tirzepatide frequently under-eat protein because appetite suppression reduces total food intake. A target of 1.2 to 1.6 g of protein per kilogram of body weight per day supports both lean mass preservation and keratin synthesis [11]. Iron-rich foods (red meat, lentils, fortified cereals) and zinc-containing foods (oysters, beef, pumpkin seeds) should be prioritized.

Supplementation should be lab-guided, not empiric. A 2017 systematic review in Dermatology and Therapy found that iron supplementation improved telogen effluvium outcomes only in patients whose ferritin was <30 ng/mL [12]. Blanket "hair vitamins" without documented deficiency add cost with no proven benefit.

Titration Pacing

Slower dose escalation may reduce the metabolic shock that triggers telogen effluvium. The Zepbound prescribing information recommends monthly dose increases (2.5 mg to 5 mg to 7.5 mg to 10 mg to 12.5 mg to 15 mg), but clinicians have discretion to hold at a given dose for longer [13]. For a patient developing Grade 2 shedding at the 10 mg dose, extending the 10 mg period from 4 weeks to 8 or 12 weeks gives the body time to adapt to the new weight trajectory.

When to Consider Stopping Zepbound

Discontinuation should be reserved for Grade 3 cases where the patient's distress outweighs the metabolic benefit of continued therapy. This is a clinical judgment call, not a reflex. Stopping tirzepatide will slow weight loss and remove the primary trigger, but it also sacrifices the cardiovascular and glycemic benefits documented in SURMOUNT and SURPASS [3][5][6]. The decision should be made collaboratively, with the patient fully informed that hair regrowth typically begins within 3 to 6 months of trigger removal.

Monitoring and Follow-Up Schedule

A structured monitoring plan helps clinicians catch hair loss early and intervene before it reaches Grade 3.

Baseline (Before or at Initiation)

Obtain ferritin, serum zinc, 25-hydroxyvitamin D, CBC, TSH, and a dietary protein intake estimate. Document baseline hair density if possible (a simple parted-hair photograph with a smartphone is sufficient). These baseline values allow meaningful comparison if shedding develops later.

Month 3 to 6 (Peak Risk Window)

This is the period when telogen effluvium most commonly presents. Ask about shedding at every visit. Perform a hair pull test if the patient reports increased loss. Recheck ferritin and zinc if baseline values were borderline. A ferritin decline from 45 to 18 ng/mL over 3 months, for example, warrants supplementation even if it is technically above the "deficiency" cutoff of 12 ng/mL.

Month 6 to 12 (Resolution Phase)

Most patients with Grade 1 or Grade 2 telogen effluvium see shedding stabilize by month 6 and notice regrowth by month 9 to 12. If shedding worsens or fails to plateau by month 9, consider dermatology referral and scalp biopsy to rule out concurrent androgenetic alopecia or another diagnosis. A 2020 study in the International Journal of Dermatology reported that 12% of patients initially diagnosed with telogen effluvium had overlapping androgenetic alopecia that only became apparent as diffuse shedding unmasked the underlying pattern [14].

Differentiating Telogen Effluvium from Other Causes

Not all hair loss during Zepbound therapy is telogen effluvium. Clinicians should maintain a differential.

Androgenetic Alopecia

This is pattern hair loss (frontal recession in men, widening midline part in women) with a genetic basis. It can coexist with telogen effluvium and become more noticeable as diffuse shedding thins the surrounding hair. Dermoscopy showing miniaturized follicles suggests androgenetic alopecia rather than pure telogen effluvium [15].

Thyroid Dysfunction

Both hypothyroidism and hyperthyroidism cause diffuse hair loss. TSH should be checked at baseline and repeated if hair loss persists beyond expected timelines. Tirzepatide does not directly affect thyroid function, but rapid weight changes can alter thyroid hormone metabolism [16].

Alopecia Areata

Patchy, well-demarcated areas of hair loss suggest alopecia areata, an autoimmune condition unrelated to weight loss. Exclamation-point hairs on dermoscopy are pathognomonic. This requires dermatology referral and a separate treatment pathway.

Iron Deficiency Anemia

Distinct from low ferritin without anemia. Hemoglobin <12 g/dL in women or <13 g/dL in men with low ferritin demands iron repletion and investigation of the cause (GI blood loss, heavy menses, malabsorption) before attributing hair loss solely to tirzepatide-related weight loss [4].

Comparing Hair Loss Across GLP-1 Receptor Agonists

Hair loss is not unique to tirzepatide. Semaglutide trials reported similar rates.

In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks, and alopecia was reported in 3.0% of the semaglutide group versus 1.0% on placebo [17]. The higher alopecia rates in SURMOUNT-1 (4.6 to 5.7%) likely reflect the greater weight loss achieved with tirzepatide (20.9% at the highest dose) rather than a difference in follicular toxicity between the two molecules.

A 2024 retrospective cohort analysis published in Obesity (N=4,812) compared alopecia incidence across semaglutide, tirzepatide, and liraglutide. After adjusting for percentage of body weight lost, the odds ratios for alopecia were statistically indistinguishable among all three agents (adjusted OR range 0.91 to 1.12) [18]. The American Association of Clinical Endocrinology (AACE) 2023 obesity guideline acknowledges telogen effluvium as a class-wide weight-loss phenomenon and recommends nutritional counseling as a preventive strategy [19].